RxDoctor Payments Data

Andrew Shahan, MD

Family Medicine · Lincoln, NENPI 1083978134

Payments from drug & device makers

$3,025in general payments, 2019–2025

Across 164 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$403
  • Bayer$237
  • Otsuka America Pharmaceutical, Inc.$212
  • Amgen$139
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$136
  • plus $798 from 22 others

What the payments were for

  • Food & beverage$3,025100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,025 in reported general payments places this provider in the 80th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$1,851
Medicare patients
35
Services billed
91

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin91$82,687
OzempicSemaglutide44$57,393
TrulicityDulaglutide16$36,973
FarxigaDapagliflozin Propanediol17$25,163
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$19,549
EliquisApixaban19$19,192
MyrbetriqMirabegron26$14,259
JanuviaSitagliptin Phosphate16$11,756
KerendiaFinerenone14$10,373
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$3,166
Atorvastatin Calcium273$2,343
Gabapentin70$1,435
Omeprazole119$1,406
Albuterol Sulfate HfaAlbuterol Sulfate53$1,349
Venlafaxine Hcl ErVenlafaxine Hcl12$1,335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$78$82,68791 claims
Novo NordiskOzempic$403$57,39344 claims
Lilly USA, LLCTrulicity, Olanzapine$34$37,48833 claims
AstraZenecaFarxiga$11$25,16317 claims
GSKTrelegy Ellipta$72$19,54925 claims
PfizerEliquis$55$19,19219 claims
Astellas Pharma US IncMyrbetriq$86$14,25926 claims
MerckJanuvia$44$11,75616 claims
BayerKerendia$237$10,37314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →